Hoang G. Nguyen
Hanoi, Viet Nam
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Treatment-Emergent Isolated EGFR C797S Mutation Following First-Line Osimertinib-Based Combination Therapy: A Case Report and Literature Review.
Journal: Respirology case reports
Published: May 20, 2026
First-Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases: A Real-World Multicenter Study from Vietnam.
Journal: Thoracic cancer
Published: May 13, 2026
Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.
Journal: Therapeutic advances in respiratory disease
Published: May 25, 2025
Optimizing afatinib dosage: enhancing treatment outcomes and minimizing toxicities in advanced EGFR-mutated non-small cell lung cancer patients in Vietnam.
Journal: Therapeutic advances in medical oncology
Published: April 29, 2025
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.
Journal: The Lancet. Respiratory medicine
Published: November 25, 2024
The Effectiveness of Afatinib as First-Line Treatment in Vietnamese Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases.
Journal: Asia-Pacific journal of clinical oncology
Published: May 06, 2024
Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Journal: Therapeutic advances in medical oncology
Published: July 15, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026